샘플 요청 목록

 카트 문의
시장보고서
상품코드
1433613

세계의 체외 독성 시험 시장 규모, 점유율 및 동향 분석 보고서 : 기술별, 최종 용도별, 용도별, 방법별, 제품별, 지역별, 부문별 예측(2024-2030년)

In-vitro Toxicology Testing Market Size, Share & Trends Analysis Report By Technology (Cell Culture, High Throughput), By End-use, By Application, By Method (Cellular Assay), By Product, By Region, And Segment Forecasts, 2024 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 117 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

체외 독성 시험 시장 성장 및 동향 :

세계 체외 독성 테스트 시장 규모는 2030년까지 648억 1,000만 달러에 달할 것으로 예측되며, 2024-2030년 연평균 11.17% 성장할 것으로 예측됩니다. 수년 동안 규제 당국의 체외 독성 테스트 방법의 수용이 빠른 속도로 증가하고 있으며, 그 결과 전통적인 테스트와 달리 이러한 테스트 방법에 대한 검증이 더욱 강화되고 있습니다.

또한, 독성시험의 동물실험을 대체할 수 있는 기술 개발로 인실리코(In-silico) 시뮬레이션, 분석, 3D 세포배양 등 체외모델의 활용이 촉진되면서 시장 성장을 견인하고 있습니다.

신약 후보물질의 스크리닝을 위해서는 전임상시험에 동물을 사용해야 하는데, 이는 매우 번거롭고 비용이 많이 듭니다. 하지만 최근에는 동물실험 금지를 추진하는 국가들도 생겨나고 있습니다. 예를 들어, EU는 몇년전부터 동물실험의 축소, 대체, 개선을 추진하고 있습니다. 화장품에 관한 규정(1223/2009), REACH(2007/2006), 과학적 목적으로 사용되는 동물의 보호에 관한 지침(2010/63), 분류, 표시, 포장(CLP)(1272/2008) 등은 동물 독성 시험의 대체를 강력하게 장려하는 EU 법의 일례입니다. 또한 2018년 6월에는 캘리포니아 주에서 2020년 이후 동물실험 제품 판매를 금지하는 'Cruelty-Free Cosmetics Act'가 통과되었습니다.

많은 정부 및 민간 단체들이 전통적인 시험 모델을 최소화하고 체외(In-vitro) 독성 테스트 방법을 지원 및 개발하기 위해 자금을 제공하고 정부 정책을 촉진하기 위한 조치를 취하고 있습니다. 이처럼 동물실험 금지에 중점을 둔 정부 이니셔티브 증가는 체외 독성학 모델의 채택 증가의 원인이 되고 있으며, 시장 내 많은 기회를 창출하고 있습니다. 예를 들어, 동물의 윤리적 대우를 요구하는 사람들의 모임(PETA)과 그 국제 관련 단체는 비동물 실험법 개발을 촉진하기 위해 약 320만 달러를 기부했습니다.

생물학적, 하이스루풋, 화학적 방법 등 계산 및 스크리닝 기법의 발전은 독성 분석을 위한 방대한 수의 공개 데이터베이스와 결합하여 크게 확대되었습니다. 이를 통해 연구자들은 신약 개발 연구, 독성 프로파일링 및 의약품 개발 프로그램을 위한 정보에 접근할 수 있게 되었습니다. 예를 들어, Agilent Technologies, Inc.의 MetaTox HS 프로젝트는 의약품 개발 절차에서 독성 분석 및 고감도 대사를 위한 고급 솔루션을 제공합니다.

인비트로(체외) 독성 시험 시장 보고서 하이라이트 :

  • 기술별로는 세포 배양 기술 부문이 2023년 세계 시장에서 43.88% 시장 점유율을 차지할 것으로 예상되며, 이는 정확하고 비용 효율적인 분석에 대한 수요 증가에 기인합니다. 또한, 3D 세포배양의 채택도 이 부문의 성장을 가속하고 있습니다.
  • 용도별로는 전신독성학 분야가 2023년 시장을 주도할 것으로 예상됩니다. 최소 용량, 내성 용량, 위험 평가 등 독성학 데이터 포인트 생성은 수익 창출에 기여하고 있습니다.
  • 세포 분석은 세포 기반 이미징 분석, 하이스루풋 스크리닝, 무표지 검출의 개발로 인해 예측 기간 동안 가장 큰 매출 점유율을 차지하며 성장할 것으로 예상됩니다.
  • 2023년 시장에서는 제약 산업의 최종 용도 부문이 큰 비중을 차지했습니다. 의약품 개발 단계에서 독성 테스트의 중요성은 많은 제품 파이프라인과 함께 수익 창출의 주요 요인으로 작용하고 있습니다.
  • 북미가 2023년 47.73%의 점유율을 차지하며 시장을 주도할 것으로 예상되는데, 이는 동물실험 금지의 확산과 독성학 연구에 대한 정부의 지원책에 기인합니다. 또한, 이 지역에는 체외 시험 제품 및 서비스를 제공하는 기업들이 밀집해 있어 예측 기간 동안 수익 창출이 지속될 것으로 보입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 체외 독성 시험 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 상위 시장 전망
    • 관련/부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 체외 독성 시험 시장 분석 툴
    • Porter의 Five Forces 분석
    • PESTEL 분석
    • 가격 분석

제4장 체외 독성 시험 시장 : 기술 추정·동향 분석

  • 부문 대시보드
  • 체외 독성 시험 시장 : 기술 변동 분석(2023년·2030년)
  • 세포배양 기술
  • 하이스루풋(High throughput) 기술
  • 분자 이미징
  • 오믹스테크노로지

제5장 체외 독성 시험 시장 : 제품 추정·동향 분석

  • 부문 대시보드
  • 체외 독성 시험 시장 : 제품 변동 분석(2023년·2030년)
  • 소모품
  • 어세이
  • 기기
  • 소프트웨어
  • 서비스

제6장 체외 독성 시험 시장 : 용도 추정·동향 분석

  • 부문 대시보드
  • 체외 독성 시험 시장 : 용도 변동 분석(2023년·2030년)
  • 전신 독성
  • 경피 독성
  • 내분비 교란
  • 눈 독성
  • 기타 독성

제7장 체외 독성 시험 시장 : 방법 추정·동향 분석

  • 부문 대시보드
  • 체외 독성 시험 시장 : 방법 변동 분석(2023년·2030년)
  • 세포 어세이
  • 생화학적 어세이
  • In-silico
  • Ex-vivo

제8장 체외 독성 시험 시장 : 최종 용도 추정·동향 분석

  • 부문 대시보드
  • 체외 독성 시험 시장 : 최종 용도 변동 분석(2023년·2030년)
  • 제약 산업
  • 화장품 및 가정용품
  • 학술기관 및 연구기관
  • 진단
  • 화학공업
  • 식품 업계

제9장 체외 독성 시험 시장 : 지역 추정·동향 분석

  • 체외 독성 시험 시장 점유율 : 지역별(2023년·2030년)
  • 북미
    • 북미의 체외 독성 시험 시장 추정·예측(2018년-2030년)
    • 미국
    • 캐나다
  • 유럽
    • 유럽의 체외 독성 시험 시장 추정·예측(2018년-2030년)
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 스웨덴
    • 덴마크
    • 노르웨이
  • 아시아태평양
    • 아시아태평양의 체외 독성 시험 시장 추정·예측(2018년-2030년)
    • 중국
    • 일본
    • 인도
    • 한국
    • 호주
    • 태국
  • 라틴아메리카
    • 라틴아메리카의 체외 독성 시험 시장 추정·예측(2018년-2030년)
    • 브라질
    • 멕시코
    • 아르헨티나
  • 중동 및 아프리카
    • 중동 및 아프리카의 체외 독성 시험 시장 추정·예측(2018년-2030년)
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 남아프리카공화국
    • 쿠웨이트

제10장 경쟁 구도

  • 주요 시장 진출기업의 최근 동향과 영향 분석
  • 기업 분류
  • 기업의 시장 점유율 분석(2023년)
  • 기업 히트맵 분석
  • 전략 매핑
    • 사업 확대
    • 인수합병(M&A)
    • 파트너십과 협업
    • 신제품 발매
    • 연구개발
  • 기업 개요
    • Charles River Laboratories International, Inc
    • SGS SA
    • Merck KGaA
    • Eurofins Scientific
    • Abbott Laboratories
    • Laboratory Corporation of America Holdings
    • Evotec SE
    • Thermo Fisher Scientific, Inc.
    • Quest Diagnostics Incorporated
    • Agilent Technologies, Inc.
    • Catalent, Inc.
    • Danaher
    • Bio-Rad Laboratories, Inc
    • BioIVT
    • Gentronix
LSH 24.03.18

In-vitro Toxicology Testing Market Growth & Trends:

The global in-vitro toxicology testing market size is expected to reach USD 64.81 billion by 2030, registering a CAGR of 11.17% from 2024 to 2030, according to a new report by Grand View Research, Inc. Over the years, acceptance of in-vitro toxicology testing methods by regulatory authorities is increasing at a faster pace & thus validation of these tests methods opposed to conventional testing is even rising. Also, development of technologies to substitute animal use for toxicology tests has fueled the usage of in-vitro models such as in-silico simulation, assays, 3D cell cultures and many more, thereby boosting market growth.

Screening of a new drug candidate involves the use of animals for preclinical studies which is very tedious and expensive. However, in recent times, several jurisdictions are promoting ban for animal-based chemical testing. For example, for several years, the EU has been promoting the reduction, replacement, and refinement of animal tests. The Regulation on cosmetic products (1223/2009), REACH (2007/2006), the Directive on the protection of animals used for scientific purposes (2010/63), and Classification, Labelling and Packaging (CLP) (1272/2008) are some examples of EU legislation that are engaged in strongly encouraging the replacement of animal toxicology testing. Furthermore, in June 2018, the Cruelty-Free Cosmetics Act was passed in California to ban the selling of animal-tested products after 2020.

Many governments and private organization are taking actions to minimize conventional testing models, providing funds to support & develop in-vitro toxicology assays and form conducive government policies. Thus, increase in government initiatives that are focused on banning animal testing can be attributed to the rise in adoption of in-vitro toxicological models and creates many opportunities within the market. For instance, approximately USD 3.2 million were contributed by People for the Ethical Treatment of Animals (PETA) and its international associates to promote the development of non-animal test methods.

The advancements in computational and screening methods such as biological, high throughput, and chemical coupled with the vast number of public databases for toxicity analysis has expanded largely. This has allowed researchers to access information for drug discovery studies, toxicology profiling, and drug development programs. For instance, the MetaTox HS project by Agilent Technologies, Inc. brings advanced solutions for toxicity assays & high sensitivity metabolism during drug development procedures.

In-vitro Toxicology Testing Market Report Highlights:

  • Based on technology, Cell culture technology segment held a dominant market share of 43.88% in the global market in 2023, owing to the increased demand for accurate & cost-effective analysis. Moreover, the adoption of 3D cell culture is also propelling the growth of this segment
  • On the basis of application, the systemic toxicology application segment dominated the market in 2023. Generation of toxicology data points such as minimum dose, tolerated dose, risk assessment and many more will contribute to the revenue generation
  • The cellular assay accounted for the largest share in terms of revenue and is expected to grow over the forecasted period, owing to the developments in cell-based imaging assays, high throughput screening & label-free detection
  • The pharmaceutical industry end-use segment held a major share in the market in 2023. The importance of toxicology testing during drug development stages coupled with high number of product pipeline attributes to the revenue generation
  • North America dominated the market and accounted for a 47.73% share in 2023 due to prevalence of animal testing bans & supportive government initiatives for toxicology research. In addition, aggregation of players in this regions to provide in-vitro testing product and services will continue the revenue generation during the forecast

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
  • 1.5. Details of primary research
    • 1.5.1. Data for primary interviews in North America
    • 1.5.2. Data for primary interviews in Europe
    • 1.5.3. Data for primary interviews in Asia Pacific
    • 1.5.4. Data for primary interviews in Latin America
    • 1.5.5. Data for Primary interviews in MEA
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
      • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.2. Volume price analysis (Model 2)
      • 1.7.2.1. Approach 2: Volume price analysis
  • 1.8. Research Scope and Assumptions
    • 1.8.1. List of Secondary Sources
    • 1.8.2. List of Primary Sources
    • 1.8.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. In-vitro Toxicology Testing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Rise in government funding for toxicology research
      • 3.2.1.2. Opposition in animal testing
      • 3.2.1.3. Ongoing developments in advanced toxicology research
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. Lack of in-vitro models
      • 3.2.2.2. Issues pertaining to standardization of in vitro studies
  • 3.3. In-vitro Toxicology Testing Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
      • 3.3.2.5. Legal landscape
    • 3.3.3. Pricing Analysis

Chapter 4. In-vitro Toxicology Testing Market: Technology Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. In-vitro Toxicology Testing Market: Technology Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Cell Culture Technology
    • 4.3.1. Cell Culture Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. High Throughput Technology
    • 4.4.1. High Throughput Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Molecular Imaging
    • 4.5.1. Molecular Imaging Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. OMICS Technology
    • 4.6.1. OMICS Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. In-vitro Toxicology Testing Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. In-vitro Toxicology Testing Market: Product Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Consumables
    • 5.3.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Assays
    • 5.4.1. Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Instruments
    • 5.5.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Software
    • 5.6.1. Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Services
    • 5.7.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. In-vitro Toxicology Testing Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. In-vitro Toxicology Testing Market: Application Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Systemic Toxicology
    • 6.3.1. Systemic Toxicology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.1.1. Acute Toxicity
      • 6.3.1.1.1. Acute Toxicity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.1.2. Carcinogenicity
      • 6.3.1.2.1. Carcinogenicity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.1.3. Developmental Toxicity
      • 6.3.1.3.1. Developmental Toxicity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.1.4. Others
      • 6.3.1.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Dermal Toxicity
    • 6.4.1. Dermal Toxicity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.1.1. Skin Irritation Test
      • 6.4.1.1.1. Skin Irritation Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.1.2. Skin Sensitization Test
      • 6.4.1.2.1. Skin Sensitization Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.1.3. Skin Corrosion Test
      • 6.4.1.3.1. Skin Corrosion Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.1.4. Phototoxicity Test
      • 6.4.1.4.1. Phototoxicity Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.1.5. Others
      • 6.4.1.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Endocrine Disruption
    • 6.5.1. Endocrine Disruption Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.5.1.1. Dioxins
      • 6.5.1.1.1. Dioxins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.5.1.2. Phthalates
      • 6.5.1.2.1. Phthalates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.5.1.3. Polychlorinated biphenyls (PCB)
      • 6.5.1.3.1. Polychlorinated biphenyls (PCB) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Ocular Toxicity
    • 6.6.1. Ocular Toxicity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.1.1. Intravitreal
      • 6.6.1.1.1. Intravitreal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.1.2. Subretinal
      • 6.6.1.2.1. Subretinal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.1.3. Others
      • 6.6.1.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Other Toxicity
      • 6.7.1.1. Other Toxicity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.7.1.2. Immunotoxicity
      • 6.7.1.2.1. Immunotoxicity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.7.1.3. Reproductive Toxicity
      • 6.7.1.3.1. Reproductive Toxicity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.7.1.4. Neurotoxicity
      • 6.7.1.4.1. Neurotoxicity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.7.1.5. Epigenetic Alterations
      • 6.7.1.5.1. Epigenetic Alterations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.7.1.6. Genotoxicity
      • 6.7.1.6.1. Genotoxicity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.7.1.7. Others
      • 6.7.1.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. In-vitro Toxicology Testing Market: Method Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. In-vitro Toxicology Testing Market: Method Movement Analysis, USD Million, 2023 & 2030
  • 7.3. Cellular Assay
    • 7.3.1. Cellular Assay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1. Live Cells
      • 7.3.1.1.1. Live Cells Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.1.1. High Throughput / High Content Screening
      • 7.3.1.1.1.1.1. High Throughput / High Content Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.1.2. Molecular Imaging
      • 7.3.1.1.1.2.1. Molecular Imaging Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.1.2.1.1. Confocal Microscopy
      • 7.3.1.1.1.2.1.1.1. Confocal Microscopy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.1.2.1.2. Others
      • 7.3.1.1.1.2.1.2.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.1.3. Others
      • 7.3.1.1.1.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.2. Fixed Cells
      • 7.3.1.2.1. Fixed Cells Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Biochemical Assay
    • 7.4.1. Biochemical Assay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. In-silico
    • 7.5.1. In-silico Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Ex-vivo
    • 7.6.1. Ex-vivo Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. In-vitro Toxicology Testing Market: End-Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. In-vitro Toxicology Testing Market: End-Use Movement Analysis, USD Million, 2023 & 2030
  • 8.3. Pharmaceutical Industry
    • 8.3.1. Pharmaceutical Industry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Cosmetics & Household Products
    • 8.4.1. Cosmetics & Household Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Academic Institutes & Research Laboratories
    • 8.5.1. Academic Institutes & Research Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Diagnostics
    • 8.6.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.1.1. Medical Devices
      • 8.6.1.1.1. Medical Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 8.6.1.2. Others
      • 8.6.1.2.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Chemicals Industry
    • 8.7.1. Chemicals Industry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Food Industry
    • 8.8.1. Food Industry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. In-vitro Toxicology Testing Market: Regional Estimates & Trend Analysis

  • 9.1. In-vitro Toxicology Testing Market Share, By Region, 2023 & 2030, USD Million
  • 9.2. North America
    • 9.2.1. North America In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. Key Country Dynamics
      • 9.2.2.2. Regulatory Landscape/Reimbursement Scenario
      • 9.2.2.3. Competitive Insights
      • 9.2.2.4. U.S. In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3. Canada
      • 9.2.3.1. Key Country Dynamics
      • 9.2.3.2. Regulatory Landscape/Reimbursement Scenario
      • 9.2.3.3. Competitive Insights
      • 9.2.3.4. Canada In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. Key Country Dynamics
      • 9.3.2.2. Regulatory Landscape/Reimbursement Scenario
      • 9.3.2.3. Competitive Insights
      • 9.3.2.4. UK In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Key Country Dynamics
      • 9.3.3.2. Regulatory Landscape/Reimbursement Scenario
      • 9.3.3.3. Competitive Insights
      • 9.3.3.4. Germany In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4. France
      • 9.3.4.1. Key Country Dynamics
      • 9.3.4.2. Regulatory Landscape/Reimbursement Scenario
      • 9.3.4.3. Competitive Insights
      • 9.3.4.4. France In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5. Italy
      • 9.3.5.1. Key Country Dynamics
      • 9.3.5.2. Regulatory Landscape/Reimbursement Scenario
      • 9.3.5.3. Competitive Insights
      • 9.3.5.4. Italy In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6. Spain
      • 9.3.6.1. Key Country Dynamics
      • 9.3.6.2. Regulatory Landscape/Reimbursement Scenario
      • 9.3.6.3. Competitive Insights
      • 9.3.6.4. Spain In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7. Sweden
      • 9.3.7.1. Key Country Dynamics
      • 9.3.7.2. Regulatory Landscape/Reimbursement Scenario
      • 9.3.7.3. Competitive Insights
      • 9.3.7.4. Sweden In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.8. Denmark
      • 9.3.8.1. Key Country Dynamics
      • 9.3.8.2. Regulatory Landscape/Reimbursement Scenario
      • 9.3.8.3. Competitive Insights
      • 9.3.8.4. Denmark In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.9. Norway
      • 9.3.9.1. Key Country Dynamics
      • 9.3.9.2. Regulatory Landscape/Reimbursement Scenario
      • 9.3.9.3. Competitive Insights
      • 9.3.9.4. Norway In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. China
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Regulatory Landscape/Reimbursement Scenario
      • 9.4.2.3. Competitive Insights
      • 9.4.2.4. China In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. Japan
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Regulatory Landscape/Reimbursement Scenario
      • 9.4.3.3. Competitive Insights
      • 9.4.3.4. Japan In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. India
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Regulatory Landscape/Reimbursement Scenario
      • 9.4.4.3. Competitive Insights
      • 9.4.4.4. India In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5. South Korea
      • 9.4.5.1. Key Country Dynamics
      • 9.4.5.2. Regulatory Landscape/Reimbursement Scenario
      • 9.4.5.3. Competitive Insights
      • 9.4.5.4. South Korea In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.6. Australia
      • 9.4.6.1. Key Country Dynamics
      • 9.4.6.2. Regulatory Landscape/Reimbursement Scenario
      • 9.4.6.3. Competitive Insights
      • 9.4.6.4. Australia In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.7. Thailand
      • 9.4.7.1. Key Country Dynamics
      • 9.4.7.2. Regulatory Landscape/Reimbursement Scenario
      • 9.4.7.3. Competitive Insights
      • 9.4.7.4. Thailand In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Regulatory Landscape/Reimbursement Scenario
      • 9.5.2.3. Competitive Insights
      • 9.5.2.4. Brazil In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. Mexico
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Regulatory Landscape/Reimbursement Scenario
      • 9.5.3.3. Competitive Insights
      • 9.5.3.4. Mexico In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.4. Argentina
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Regulatory Landscape/Reimbursement Scenario
      • 9.5.4.3. Competitive Insights
      • 9.5.4.4. Argentina In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Middle East and Africa In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. Saudi Arabia
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Regulatory Landscape/Reimbursement Scenario
      • 9.6.2.3. Competitive Insights
      • 9.6.2.4. Saudi Arabia In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. UAE
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Regulatory Landscape/Reimbursement Scenario
      • 9.6.3.3. Competitive Insights
      • 9.6.3.4. UAE In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4. South Africa
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Regulatory Landscape/Reimbursement Scenario
      • 9.6.4.3. Competitive Insights
      • 9.6.4.4. South Africa In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5. Kuwait
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Regulatory Landscape/Reimbursement Scenario
      • 9.6.5.3. Competitive Insights
      • 9.6.5.4. Kuwait In-vitro Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis by Key Market Participants
  • 10.2. Company Categorization
  • 10.3. Company Market Share Analysis, 2023
  • 10.4. Company Heat Map Analysis
  • 10.5. Strategy Mapping
    • 10.5.1. Expansion
    • 10.5.2. Mergers & Acquisition
    • 10.5.3. Partnerships & Collaborations
    • 10.5.4. New Product Launches
    • 10.5.5. Research And Development
  • 10.6. Company Profiles
    • 10.6.1. Charles River Laboratories International, Inc
      • 10.6.1.1. Participant's Overview
      • 10.6.1.2. Financial Performance
      • 10.6.1.3. Product Benchmarking
      • 10.6.1.4. Recent Developments
    • 10.6.2. SGS S.A
      • 10.6.2.1. Participant's Overview
      • 10.6.2.2. Financial Performance
      • 10.6.2.3. Product Benchmarking
      • 10.6.2.4. Recent Developments
    • 10.6.3. Merck KGaA
      • 10.6.3.1. Participant's Overview
      • 10.6.3.2. Financial Performance
      • 10.6.3.3. Product Benchmarking
      • 10.6.3.4. Recent Developments
    • 10.6.4. Eurofins Scientific
      • 10.6.4.1. Participant's Overview
      • 10.6.4.2. Financial Performance
      • 10.6.4.3. Product Benchmarking
      • 10.6.4.4. Recent Developments
    • 10.6.5. Abbott Laboratories
      • 10.6.5.1. Participant's Overview
      • 10.6.5.2. Financial Performance
      • 10.6.5.3. Product Benchmarking
      • 10.6.5.4. Recent Developments
    • 10.6.6. Laboratory Corporation of America Holdings
      • 10.6.6.1. Participant's Overview
      • 10.6.6.2. Financial Performance
      • 10.6.6.3. Product Benchmarking
      • 10.6.6.4. Recent Developments
    • 10.6.7. Evotec S.E
      • 10.6.7.1. Participant's Overview
      • 10.6.7.2. Financial Performance
      • 10.6.7.3. Product Benchmarking
      • 10.6.7.4. Recent Developments
    • 10.6.8. Thermo Fisher Scientific, Inc.
      • 10.6.8.1. Participant's Overview
      • 10.6.8.2. Financial Performance
      • 10.6.8.3. Product Benchmarking
      • 10.6.8.4. Recent Developments
    • 10.6.9. Quest Diagnostics Incorporated
      • 10.6.9.1. Participant's Overview
      • 10.6.9.2. Financial Performance
      • 10.6.9.3. Product Benchmarking
      • 10.6.9.4. Recent Developments
    • 10.6.10. Agilent Technologies, Inc.
      • 10.6.10.1. Participant's Overview
      • 10.6.10.2. Financial Performance
      • 10.6.10.3. Product Benchmarking
      • 10.6.10.4. Recent Developments
    • 10.6.11. Catalent, Inc.
      • 10.6.11.1. Participant's Overview
      • 10.6.11.2. Financial Performance
      • 10.6.11.3. Product Benchmarking
      • 10.6.11.4. Recent Developments
    • 10.6.12. Danaher
      • 10.6.12.1. Participant's Overview
      • 10.6.12.2. Financial Performance
      • 10.6.12.3. Product Benchmarking
      • 10.6.12.4. Recent Developments
    • 10.6.13. Bio-Rad Laboratories, Inc
      • 10.6.13.1. Participant's Overview
      • 10.6.13.2. Financial Performance
      • 10.6.13.3. Product Benchmarking
      • 10.6.13.4. Recent Developments
    • 10.6.14. BioIVT
      • 10.6.14.1. Participant's Overview
      • 10.6.14.2. Financial Performance
      • 10.6.14.3. Product Benchmarking
      • 10.6.14.4. Recent Developments
    • 10.6.15. Gentronix
      • 10.6.15.1. Participant's Overview
      • 10.6.15.2. Financial Performance
      • 10.6.15.3. Product Benchmarking
      • 10.6.15.4. Recent Developments
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제